$2.46 Billion is the total value of Cormorant Asset Management, LP's 88 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | ERASCA INC | $216,845,000 | – | 10,505,550 | +100.0% | 8.81% | – | |
New | IMMUNEERING CORP | $58,451,000 | – | 2,252,626 | +100.0% | 2.38% | – | |
New | TANGO THERAPEUTICS INC | $48,814,000 | – | 3,899,185 | +100.0% | 1.98% | – | |
CYTK | New | CYTOKINETICS INC | $35,740,000 | – | 1,000,000 | +100.0% | 1.45% | – |
New | TYRA BIOSCIENCES INC | $18,154,000 | – | 1,069,932 | +100.0% | 0.74% | – | |
IMAB | New | I MABsponsored ads | $14,498,000 | – | 200,000 | +100.0% | 0.59% | – |
New | ICOSAVAX INC | $12,238,000 | – | 426,393 | +100.0% | 0.50% | – | |
TVTX | New | TRAVERE THERAPEUTICS INC | $8,488,000 | – | 350,000 | +100.0% | 0.34% | – |
New | ASTRIA THERAPEUTICS INC | $4,888,000 | – | 552,903 | +100.0% | 0.20% | – | |
New | RENOVACOR INC | $4,525,000 | – | 500,000 | +100.0% | 0.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
OMEROS CORP | 27 | Q3 2021 | 6.5% |
MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-29 |
4 | 2024-04-22 |
SC 13G/A | 2024-04-15 |
4 | 2024-04-03 |
SC 13G | 2024-03-21 |
4 | 2024-03-18 |
SC 13G/A | 2024-03-18 |
4 | 2024-03-11 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.